Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Patient-Centered Outcomes From a Randomized Clinical Trial

We thank Drs Desapriya, Khoshpouri, and Al-Isa for their comments on our Diabetic Retinopathy Clinical Research Network (DRCR.net) report on patient-centered and driving-related outcomes from the DRCR.net's Protocol S, a randomized clinical trial of ranibizumab vs panretinal photocoagulation (PRP) for proliferative diabetic retinopathy (PDR).1 Beyond their comments unrelated specifically to our findings in their first paragraph, they indicated in their second paragraph that differences in work productivity and driving-related outcomes slightly favored the ranibizumab group over the PRP group, but that the difference was not statistically significant.
Source: American Journal of Ophthalmology - Category: Opthalmology Authors: Tags: Correspondence Source Type: research